In the News

The Situation: The discovery medicine organization of a global pharmaceutical company sought to change their current working practices to embrace a model based drug development (MBDD) paradigm that would encourage quantitative data analysis and use of that analysis to provide support for early go/no-go decisions and future trial design. The organization was functionally siloed both in terms of business process and data integration. In order to achieve the necessary paradigm shift the organization recognized that change would be required across many fronts including changes in mindset and culture, changes to organizational structure and business processes, as well as the development of technical tools and infrastructure to better support access to and analysis of disparate data.